J. Goldman & Co’s TG Therapeutics TGTX Stock Holding History

J. Goldman & Co’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-54,000	Closed	-$1.34M	–	478
2023 Q2	$1.34M	Buy	+54,000	New	+$1.39M	0.05%	233

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

J. Goldman & Co's TGTX Position: Q2 2026 in Review

J. Goldman & Co sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 48,235 shares — an estimated $1.6M sold.

J. Goldman & Co first reported a position in TGTX in Q1 2020 and held it in 12 quarters. The position peaked at $4.45M in Q2 2023. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

J. Goldman & Co reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 48,235 TG Therapeutics shares in Q2 2026, an estimated $1.6M.
J. Goldman & Co first reported a position in TG Therapeutics in Q1 2020 and held it in 12 quarters.
J. Goldman & Co's TG Therapeutics position peaked at $4.45M in Q2 2023.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.